# FAK-Activated Mucosal Healing Promotes Resistance to Reinjury

## TL;DR

Activating a protein called FAK helps heal gut ulcers faster and protects against future damage from common painkillers.

## Contribution

This study shows that FAK activation promotes mucosal healing and protects against reinjury in the gastrointestinal tract.

## Key findings

- FAK activation speeds up healing of ischemic ulcers by boosting blood vessel growth.
- Mice treated with FAK activators had smaller ulcers after a second injury challenge.
- FAK activators improved healing quality, reducing vulnerability to future damage.

## Abstract

What are the main findings?
FAK activation accelerates ischemic ulcer healing, in part by enhancing angiogenesis.FAK activation during an initial injury reduces susceptibility to recurrent NSAID-induced intestinal injury.

FAK activation accelerates ischemic ulcer healing, in part by enhancing angiogenesis.

FAK activation during an initial injury reduces susceptibility to recurrent NSAID-induced intestinal injury.

What are the implications of the main findings?
FAK activation may represent a novel therapeutic avenue for gastrointestinal injury.FAK activation may be especially valuable for patients requiring long-term NSAID therapy.

FAK activation may represent a novel therapeutic avenue for gastrointestinal injury.

FAK activation may be especially valuable for patients requiring long-term NSAID therapy.

Background: Gastrointestinal (GI) mucosal injury is a frequent complication of long-term nonsteroidal anti-inflammatory drug (NSAID) use. Effective mucosal healing requires coordinated epithelial migration, proliferation, and angiogenesis, which may be influenced by focal adhesion kinase (FAK). This study aimed to determine whether our newly developed FAK activators promote intestinal mucosal healing by enhancing angiogenesis and whether FAK activation increases resistance to reinjury. Methods: Ischemic jejunal ulcers were induced in C57BL/6 mice. After 24 h, mice received intraperitoneal injections of the FAK activator ZINC40099027 (ZN27, 900 µg/kg every 6 h) or vehicle for 2, 4, or 14 days. Ulcer areas were quantified, and liver and kidney function were assessed. Ulcer and adjacent tissues were analyzed by immunofluorescence staining for angiogenesis and proliferation markers. In vitro, human umbilical vein endothelial cells (HUVECs) were treated with ZN27 to evaluate proliferation, migration, angiogenesis, and intracellular signaling. In a reinjury model, male C57BL/6J mice received continuous infusion of the FAK activator M64HCl (25 mg/kg/day) or vehicle for 7 days, with a single subcutaneous injection of indomethacin (10 mg/kg) on day 1 to induce GI injury. Fourteen days after the first dose of indomethacin, the mice received a second indomethacin challenge, and one day later, total ulcer areas in the pyloric opening and small intestine were quantified. Results: Ulcer areas were significantly smaller in ZN27-treated mice compared with vehicle-treated controls at 3 and 5 days, accompanied by increased expression of angiogenesis and proliferation markers. In vitro, ZN27 enhanced HUVEC migration via FAK activation in an ERK1/2-dependent manner and increased the number of angiogenic sprouts. In the reinjury model, treatment with M64HCl during the initial indomethacin-induced injury resulted in significantly smaller ulcer areas in both the pyloric opening and small intestine after the second indomethacin challenge compared with controls. Conclusions: FAK activation accelerates ischemic ulcer healing, in part by enhancing angiogenesis. Moreover, FAK activation during an initial injury reduces susceptibility to recurrent NSAID-induced intestinal injury, perhaps because it promotes initial higher-quality ulcer repair.